The notice further says there has been no follow-up from the hospital, the drug regulatory authority, the company or sponsors. But he “is still not stable, has severe mood swings, problems with comprehension and… (finds it) difficult to do even simple, routine things,” the complaint claims. The participant was discharged from hospital on October 26. The participant suffered “acute neuro encephalopathy,” the notice alleges. On October 11, he started experiencing severe headaches and was not able to respond to questions. Also measured CRP, D-dimers, HB, lymphocyte, serum ferritin after one week of. It was stated that the participant might experience “injection site reaction, pain, tenderness, fever, chills, fatigue, headache or joint pain, among other common symptoms.” The advocate also said the information sheet mentioned that there was a rare possibility of severe Covid infection if participants contracted the disease post-vaccination.Īccording to the notice, the participant received the vaccine on October 1. Meta-analysis of 15 trials found that ivermectin reduced risk of death. “The client was therefore led to believe that taking the Covishield test vaccine was safe and risks associated… would hardly lead to any serious side effect, leave alone severe adverse effect,” said the notice.Īccording to the Rajaram, what the participant experienced was not even remotely close to what was cited in the participant information sheet. "The client was led to believe that taking the Covishield test vaccine was safe and risks associated… would hardly lead to any serious side effect, leave alone severe adverse effect"
0 kommentar(er)
